Added to YB: 2025-07-29
Pitch date: 2025-07-26
SGMO [bullish]
Sangamo Therapeutics, Inc.
-27.42%
current return
Author Info
No bio for this author
Company Info
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
Market Cap
$142.5M
Pitch Price
$0.62
Price Target
6.00 (+1233%)
Dividend
N/A
EV/EBITDA
-1.37
P/E
-0.95
EV/Sales
4.21
Sector
Biotechnology
Category
turnaround
My #1 Biotech Conviction: Sangamo Therapeutics ($SGMO)
SGMO: Biotech turnaround with blockbuster Fabry gene therapy (best-in-class data showing kidney improvement), FDA accelerated approval path, potential partnership/buyout imminent due to cash runway ending Q3. Multiple shots on goal including HemA gene therapy, CNS platform (Roche deal), and proprietary AAV capsids licensed to Lilly/Astellas.
Read full article (30 min)